BioSpace News Archive

InflaRx N.V. (Nasdaq: IFRX) announced today that the Company has submitted a Marketing Authorization Application (MAA) for the treatment of adult patients with SARS-CoV-2 induced septic acute respiratory distress syndrome (ARDS) receiving invasive mechanical ventilation (IMV) or extracorporeal membrane oxygenation (ECMO) and that the European Medicines Agency (EMA) has validated the MAA.

Cleveland Diagnostics, Inc., a leading commercial-stage biotechnology company, is launching its inaugural Prostate Cancer Awareness Campaign this September: ‘A PSA on PSA.’

Recludix Pharma announced that Nancy Whiting, Pharm.D., chief executive officer of Recludix, will present at multiple investor conferences in September.

Sutro Biopharma, Inc., a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates, announced that Bill Newell, Chief Executive Officer, will participate in two upcoming investor conferences.

Vor Bio, a clinical-stage cell and genome engineering company, announced that it will participate in the following upcoming investor conferences.

Emergent BioSolutions Inc. announced NARCAN® Naloxone HCl Nasal Spray 4 mg will be available on shelves nationwide and online beginning in September.

Oculis Holding AG announced that Riad Sherif, MD, Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer will be attending and presenting at the following upcoming investor conferences:

Eagle Pharmaceuticals, Inc. announced that it has been selected to present a platform presentation at the Society for Neuroscience in Anesthesiology and Critical Care Annual Meeting being held September 8-10, 2023, in Alexandria, VA.

Johnson & Johnson announced updates to its financials and 2023 guidance which reflect its operations as a company focused on transformational innovation in Pharmaceutical and MedTech.

EyePoint Pharmaceuticals, Inc., a pharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, announced that the Company will participate at the following upcoming conferences.